Overview

  • Product name
    Anti-CPT1A antibody [8F6AE9] (Alexa Fluor® 488)
    See all CPT1A primary antibodies
  • Description
    Mouse monoclonal [8F6AE9] to CPT1A (Alexa Fluor® 488)
  • Host species
    Mouse
  • Conjugation
    Alexa Fluor® 488. Ex: 495nm, Em: 519nm
  • Tested applications
    Suitable for: ICC/IF, Flow Cytmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
    Does not react with: Cow
  • Immunogen

    Recombinant fragment corresponding to Human CPT1A aa 489-773 (C terminal).
    Sequence:

    MSIDSLQLGYAEDGHCKGDINPNIPYPTRLQWDIPGECQEVIETSLNTAN LLANDVDFHSFPFVAFGKGIIKKCRTSPDAFVQLALQLAHYKDMGKFCLT YEASMTRLFREGRTETVRSCTTESCDFVRAMVDPAQTVEQRLKLFKLASE KHQHMYRLAMTGSGIDRHLFCLYVVSKYLAVESPFLKEVLSEPWRLSTSQ TPQQQVELFDLENNPEYVSSGGGFGPVADDGYGVSYILVGENLINFHISS KFSCPETDSHRFGRHLKEAMTDIITLFGLSSNSKK


    Database link: P50416

  • Positive control
    • Flow cytometry: HeLa cells, HAP1-WT cells. ICC/IF: HeLa cells.
  • General notes

    Product was previously marketed under the MitoSciences sub-brand.

    Alexa Fluor® is a registered trademark of Molecular Probes, Inc, a Thermo Fisher Scientific Company. The Alexa Fluor® dye included in this product is provided under an intellectual property license from Life Technologies Corporation. As this product contains the Alexa Fluor® dye, the purchase of this product conveys to the buyer the non-transferable right to use the purchased product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). As this product contains the Alexa Fluor® dye the sale of this product is expressly conditioned on the buyer not using the product or its components, or any materials made using the product or its components, in any activity to generate revenue, which may include, but is not limited to use of the product or its components: in manufacturing; (ii) to provide a service, information, or data in return for payment (iii) for therapeutic, diagnostic or prophylactic purposes; or (iv) for resale, regardless of whether they are sold for use in research. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com.

Properties

Applications

Our Abpromise guarantee covers the use of ab171449 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF Use a concentration of 5 µg/ml.
Flow Cyt Use a concentration of 5 µg/ml.

ab171465 - Mouse monoclonal IgG2b, is suitable for use as an isotype control with this antibody.

 

Target

  • Tissue specificity
    Strong expression in kidney and heart, and lower in liver and skeletal muscle.
  • Pathway
    Lipid metabolism; fatty acid beta-oxidation.
  • Involvement in disease
    Defects in CPT1A are the cause of carnitine palmitoyltransferase 1A deficiency (CPT1AD) [MIM:255120]; also known as CPT-I deficiency or CPT1A deficiency. CPT1AD is a rare autosomal recessive metabolic disorder of long-chain fatty acid oxidation characterized by severe episodes of hypoketotic hypoglycemia usually occurring after fasting or illness. Onset is in infancy or early childhood.
  • Sequence similarities
    Belongs to the carnitine/choline acetyltransferase family.
  • Cellular localization
    Mitochondrion outer membrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • Carnitine O palmitoyltransferase 1 liver isoform antibody
    • Carnitine O palmitoyltransferase I antibody
    • Carnitine O palmitoyltransferase I liver isoform antibody
    • Carnitine O-palmitoyltransferase 1 antibody
    • Carnitine O-palmitoyltransferase I antibody
    • Carnitine palmitoyltransferase 1A (liver) antibody
    • Carnitine palmitoyltransferase 1A antibody
    • Carnitine palmitoyltransferase I antibody
    • Carnitine palmitoyltransferase I liver antibody
    • CPT 1 antibody
    • CPT I antibody
    • CPT1 antibody
    • CPT1 L antibody
    • CPT1-L antibody
    • Cpt1a antibody
    • CPT1A_HUMAN antibody
    • CPTI antibody
    • CPTI-L antibody
    • L CPT1 antibody
    • liver isoform antibody
    see all

Images

  • Overlay histogram showing HAP1 wildtype (green line) and HAP1-CPT1A  knockout cells (red line) stained with ab171449. The cells were fixed with 4% formaldehyde (10 min) and then permeabilized with 0.1% PBS-Triton X-100 for 15 min. The cells were then incubated in 1x PBS / 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (ab171449, 1µg/ml dilution) for 30 min at 22°C.

    A rabbit monoclonal IgG isotype control antibody  (ab199091) was used at the same concentration and conditions as the primary antibody (HAP1 wildtype - black line, HAP1-CPT1A    knockout - grey line). Unlabelled sample was also used as a control (this line is not shown for the purpose of simplicity).

    Acquisition of >5,000 events were collected using a 50 mW Blue laser (488nm) and 530/30 bandpass filter.

  • Flow cytometric analysis of HeLa cells (4% paraformaldehyde-fixed;  methanol-permeablized) labeling CPT1A with ab171449 at 5 µg/mL (green) compared with an isotype control ab170192 at 5 µg/mL (black).  Isotype control was labeled with a Goat Anti-mouse Alexa Fluor® 488 secondary antibody prior to signal measurement on the FL-1 channel.

  • Immunofluoresecence analysis of HeLa cells (4% paraformaldehyde-fixed, methanol-permeablized) labeling CPT1A with ab171449 at 5µg/ml overnight.  100x magnification.

    A) HeLa cells labeled with ab171449 at 5 µg/mL.
    B) HeLa cells labeled with Anti-HSP60 (1/3000, ab46798), Secondary antibody used was goat anti-rabbit Dylight-594 (1/1000, ab96897).
    C) Merged Image of A and B showing specificity of mitochondrial staining.

     

References

This product has been referenced in:
  • Felices M  et al. Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect. JCI Insight 3:N/A (2018). Read more (PubMed: 29415897) »
  • Zhang Y  et al. Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy. Cancer Cell 32:377-391.e9 (2017). Read more (PubMed: 28898698) »
See all 3 Publications for this product

Customer reviews and Q&As

Application
Flow Cytometry
Sample
Human Cell (PBMCs)
Permeabilization
Yes - BD Cytofix/Cytoperm™
Gating Strategy
lymphocytes/single cells/live cells/ CD4+ or CD8+ with subpopulations
Specification
PBMCs
Preparation
Cell harvesting/tissue preparation method: thawed PBMCs
Sample buffer: PBS/FACS buffer
Fixation
BD Cytofix/Cytoperm™

Abcam user community

Verified customer

Submitted Jun 14 2017

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up